Latest & greatest articles for screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for screening

181. Thailand’s national universal developmental screening programme for young children: action research for improved follow-up

Thailand’s national universal developmental screening programme for young children: action research for improved follow-up 1 Morrison J, et al. BMJ Glob Health 2018;3:e000589. doi:10.1136/bmjgh-2017-000589 Thailand’s national universal developmental screening programme for young children: action research for improved follow-up Joanna Morrison, 1 Issarapa Chunsuwan, 2 Petch Bunnag, 3 Petra C Gronholm, 4 Georgia Lockwood Estrin 5 Research To cite: Morrison J, Chunsuwan I, Bunnag P , et al (...) . Thailand’s national universal developmental screening programme for young children: action research for improved follow-up. BMJ Glob Health 2018;3:e000589. doi:10.1136/ bmjgh-2017-000589 PCG and GLE contributed equally. Received 1 October 2017 Revised 1 December 2017 Accepted 12 December 2017 1 Institute for Global Health, University College London, London, UK 2 Department of Pediatrics, Faculty of Medicine, Developmental and Behavioral Pediatrics, Thammasat University, Pathum Thani, Thailand 3

BMJ global health2018 Full Text: Link to full Text with Trip Pro

182. Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival

Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival ARTICLE OPEN Pan-cancer screen for mutations in non-coding elements with conservation and cancer speci?city reveals correlations with expression and survival Henrik Hornshøj 1 , Morten Muhlig Nielsen 1 , Nicholas A. Sinnott-Armstrong 2 , Michal P. Switnicki 1 , Malene Juul 1 , Tobias Madsen 1,3 , Richard Sallari 2 , Manolis Kellis 2 , Torben Ørntoft 1 (...) , Asger Hobolth 3 and Jakob Skou Pedersen 1,3 Cancer develops by accumulation of somatic driver mutations, which impact cellular function. Mutations in non-coding regulatory regions can now be studied genome-wide and further characterized by correlation with gene expression and clinical outcome to identify driver candidates. Using a new two-stage procedure, called ncDriver, we ?rst screened 507 ICGC whole-genomes from 10 cancer types for non-coding elements, in which mutations are both recurrent

NPJ genomic medicine2018 Full Text: Link to full Text with Trip Pro

183. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. OBJECTIVES: To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age. DESIGN: Analysis of genotype, PCa status, and age to select single nucleotide polymorphisms (SNPs) associated with diagnosis. These polymorphisms were incorporated into a survival analysis to estimate (...) their effects on age at diagnosis of aggressive PCa (that is, not eligible for surveillance according to National Comprehensive Cancer Network guidelines; any of Gleason score ≥7, stage T3-T4, PSA (prostate specific antigen) concentration ≥10 ng/L, nodal metastasis, distant metastasis). The resulting polygenic hazard score is an assessment of individual genetic risk. The final model was applied to an independent dataset containing genotype and PSA screening data. The hazard score was calculated

BMJ2018 Full Text: Link to full Text with Trip Pro

184. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. Importance: Given recent advances in screening mammography and adjuvant therapy (treatment), quantifying their separate and combined effects on US breast cancer mortality reductions by molecular subtype could guide future decisions to reduce disease burden. Objective: To evaluate the contributions associated with screening and treatment to breast cancer mortality reductions (...) : Screening mammography and treatment. Main Outcomes and Measures: The models compared age-adjusted, overall, and ER/ERBB2-specific breast cancer mortality rates from 2000 to 2012 for women aged 30 to 79 years relative to the estimated mortality rate in the absence of screening and treatment (baseline rate); mortality reductions were apportioned to screening and treatment. Results: In 2000, the estimated reduction in overall breast cancer mortality rate was 37% (model range, 27%-42%) relative

JAMA2018 Full Text: Link to full Text with Trip Pro

185. Screening for Adolescent Idiopathic Scoliosis: US Preventive Services Task Force Recommendation Statement.

Screening for Adolescent Idiopathic Scoliosis: US Preventive Services Task Force Recommendation Statement. Importance: Adolescent idiopathic scoliosis, a lateral curvature of the spine of unknown cause with a Cobb angle of at least 10°, occurs in children and adolescents aged 10 to 18 years. Idiopathic scoliosis is the most common form and usually worsens during adolescence before skeletal maturity. Severe spinal curvature may be associated with adverse long-term health outcomes (eg, pulmonary (...) disorders, disability, back pain, psychological effects, cosmetic issues, and reduced quality of life). Early identification and effective treatment of mild scoliosis could slow or stop curvature progression before skeletal maturity, thereby improving long-term outcomes in adulthood. Objective: To update the 2004 US Preventive Services Task Force (USPSTF) recommendation on screening for idiopathic scoliosis in asymptomatic adolescents. Evidence Review: The USPSTF reviewed the evidence on the benefits

JAMA2018

186. Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis.

Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis. Background: Targeting low-dose computed tomography (LDCT) for lung cancer screening to persons at highest risk for lung cancer mortality has been suggested to improve screening efficiency. Objective: To quantify the value of risk-targeted selection for lung cancer screening compared with National Lung Screening Trial (NLST) eligibility criteria. Design: Cost-effectiveness analysis using a multistate prediction model. Data (...) Sources: NLST. Target Population: Current and former smokers eligible for lung cancer screening. Time Horizon: Lifetime. Perspective: Health care sector. Intervention: Risk-targeted versus NLST-based screening. Outcome Measures: Incremental 7-year mortality, life expectancy, quality-adjusted life-years (QALYs), costs, and cost-effectiveness of screening with LDCT versus chest radiography at each decile of lung cancer mortality risk. Results of Base-Case Analysis: Participants at greater risk for lung

Annals of Internal Medicine2018

187. Acceptance of Cervical Cancer Screening and its Correlates Among Women of a Peri-Urban High-Density Residential Area in Ndola, Zambia

Acceptance of Cervical Cancer Screening and its Correlates Among Women of a Peri-Urban High-Density Residential Area in Ndola, Zambia 30305986 2018 11 14 2161-8674 7 1 2018 International journal of MCH and AIDS Int J MCH AIDS Acceptance of Cervical Cancer Screening and its Correlates Among Women of a Peri-Urban High-Density Residential Area in Ndola, Zambia. 17-27 10.21106/ijma.223 Zambia has one of the highest cervical cancer incidence and mortality rates in the world. Cervical cancer (...) screening leads to reduction in the incidence of invasive disease. The objectives of the study were to determine the level of acceptance of cervical cancer screening and its correlates among women of a peri-urban high-density residential area in Ndola, Zambia. A cross sectional study was conducted. With a population size of 12,000 women in reproductive age and using an expected frequency of 50 + 5% and at 95% confidence interval, the required sample size was 372. A stratified sampling method was used

International journal of MCH and AIDS2018 Full Text: Link to full Text with Trip Pro

188. Breast Cancer Screening Behaviors of First Degree Relatives of Women Receiving Breast Cancer Treatment and the Affecting Factors

Breast Cancer Screening Behaviors of First Degree Relatives of Women Receiving Breast Cancer Treatment and the Affecting Factors Original Article Introduction Breast cancer is the most common cancer among females in Turkey. Incidence rate in the year 2008 was 40.7 in 100,000 and this rate increased to 43 in 2014 (1). Breast cancer incidence in Turkey is similar to the other developing countries but mortality is higher when compared with these countries (2). The best way to fight cancer (...) groups, the breast cancer rate was higher in sisters of women with breast cancer when compared to women without familial breast cancer (8). Early diagnosis and treatment are crucial in preventing and reducing cancer-related deaths in high risk groups (9-10). Family history is an unchangeable risk factor and when it is present, early diagnosis can be possible by opportunistic screening programs and medical counseling (11). American Cancer Society (ACS) recommends annual magnetic resonance imaging

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

189. Final recommendation statement: adolescent idiopathic scoliosis: screening.

Final recommendation statement: adolescent idiopathic scoliosis: screening. Final recommendation statement: adolescent idiopathic scoliosis: screening. | National Guideline Clearinghouse success fail May JUN 09 2017 2018 2019 19 May 2018 - 13 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history (...) at . TIMESTAMPS Search Sign In Username or Email * Password * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Summary NGC:011319 2018 Jan NEATS Assessment Final recommendation statement: adolescent idiopathic scoliosis: screening. Final recommendation statement

National Guideline Clearinghouse (partial archive)2018

190. Screening for Prostate Cancer*

Screening for Prostate Cancer* Screening for Prostate Cancer | National Guideline Clearinghouse success fail JUL Aug 12 2018 2019 30 Sep 2016 - 13 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested parties, and has expanded (...) ? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Synthesis Screening for Prostate Cancer Guidelines Being Compared: American College of Physicians (ACP) Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. 2013 Apr

National Guideline Clearinghouse (partial archive)2018

191. Targeted HIV Screening in Eight Emergency Departments: The DICI-VIH Cluster-Randomized Two-Period Crossover Trial

Targeted HIV Screening in Eight Emergency Departments: The DICI-VIH Cluster-Randomized Two-Period Crossover Trial 29092761 2017 11 02 1097-6760 2017 Oct 30 Annals of emergency medicine Ann Emerg Med Targeted HIV Screening in Eight Emergency Departments: The DICI-VIH Cluster-Randomized Two-Period Crossover Trial. S0196-0644(17)31660-8 10.1016/j.annemergmed.2017.09.011 This study compares the effectiveness and cost-effectiveness of nurse-driven targeted HIV screening alongside physician-directed (...) ). The incremental cost was €1,324 per additional new diagnosis. The combined strategy of targeted screening and diagnostic testing was effective. Copyright © 2017 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved. Leblanc Judith J Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier des Hôpitaux Universitaires Est Parisien, Clinical Research Center of East of Paris, Paris, France; Université Paris Saclay-Université Versailles St Quentin, INSERM UMR 1173, Garches

EvidenceUpdates2018

192. Results from clinical effectiveness evaluations of screening for colorectal cancer: rapid review

Results from clinical effectiveness evaluations of screening for colorectal cancer: rapid review Results from clinical effectiveness evaluations of screening for colorectal cancer: rapid review - NIPH Selected items added to basket Close Vis søkefelt How can we help you today? Search for: Søk Menu • • Results from clinical effectiveness evaluations of screening for colorectal cancer: rapid review Søk i Folkehelsa.no Search for: Søk Infectious diseases & Vaccines Close Mental & Physical health (...) Close Environment & Lifestyle Close Health in Norway Close Quality & Knowledge Close Research & Access to data Close Key message Background Most cases of colorectal cancer develop from benign precursors, so-called adenomas in the colon. Thus, methods for detecting colorectal cancers and its precursors are of major interest. One relevant approach is to conduct mass investigations of the population, or parts of it – “screening”. Commission As of now, two methods for colorectal cancer screening have

The Norwegian Knowledge Centre for the Health Services2018

193. Expected impact of introducing screening for colorectal cancer in Norway

Expected impact of introducing screening for colorectal cancer in Norway Expected impact of introducing screening for colorectal cancer in Norway - NIPH Selected items added to basket Close Vis søkefelt How can we help you today? Search for: Søk Menu • • Expected impact of introducing screening for colorectal cancer in Norway Søk i Folkehelsa.no Search for: Søk Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway Close Quality (...) & Knowledge Close Research & Access to data Close Published 14.11.2011 Updated 14.11.2017 Om screening Address/contact Norwegian Institute of Public Health PO Box 4404 Nydalen N-0403 Oslo PO Box 973 Sentrum N-5808 Bergen Switchboard: (+47) 21 07 70 00 Org. no. 983 744 516 Latest All our Keep up-to-date 1.0.0.1634 - FHI-PRD-WEB02 - Research overview

The Norwegian Knowledge Centre for the Health Services2018

194. Requesting the new Cervical Screening Test: what providers need to know

Requesting the new Cervical Screening Test: what providers need to know Requesting the new Cervical Screening Test: what providers need to know | RADAR 20 Years Of Helping Australians Make Better Decisions About Medicines, Medical Tests And Other Health Technologies. Log in Facebook Twitter LinkedIn Google Signing you in Use another account OR Login Form Email Password Log in to NPS MedicineWise Don't have an account? Forgot password Forgot password Email Send reset instructions Set new (...) Privacy and terms I have read the and accept the Subscribe Breadcrumbs Requesting the new Cervical Screening Test: what providers need to know Article Sections Requesting the new Cervical Screening Test: what providers need to know 1 Dec 2017 8 min read Tags Share Share to: Print Larger text Smaller text This will in turn support the ongoing monitoring and evaluation of the new NCSP. There are new conventions for requesting tests but any additional clinical information that supports the screening

National Prescribing Service Limited (Australia)2018

195. Sensitivity of the DN4 in Screening for Neuropathic Pain Syndromes

Sensitivity of the DN4 in Screening for Neuropathic Pain Syndromes 28481836 2017 12 04 1536-5409 34 1 2018 Jan The Clinical journal of pain Clin J Pain Sensitivity of the DN4 in Screening for Neuropathic Pain Syndromes. 30-36 10.1097/AJP.0000000000000512 Several tools have been developed to screen for neuropathic pain. This study examined the sensitivity of the Douleur Neuropathique en 4 Questions (DN4) in screening for various neuropathic pain syndromes. This prospective observational study (...) % were female; 83% (n=652/789) screened positive on the DN4 (≥4/10). The sensitivity was highest for central neuropathic pain (92.5%, n=74/80) and generalized polyneuropathies (92.1%, n=139/151), and lowest for trigeminal neuralgia (69.2%, n=36/52). After controlling for confounders, the sensitivity of the DN4 remained significantly higher for individuals with generalized polyneuropathies (odds ratio [OR]=4.35; 95% confidence interval [CI]: 2.15, 8.81), central neuropathic pain (OR=3.76; 95% CI: 1.56

EvidenceUpdates2018

196. Improving Health Screening Uptake in Men: A Systematic Review and Meta-analysis

Improving Health Screening Uptake in Men: A Systematic Review and Meta-analysis 29254551 2017 12 19 1873-2607 54 1 2018 Jan American journal of preventive medicine Am J Prev Med Improving Health Screening Uptake in Men: A Systematic Review and Meta-analysis. 133-143 S0749-3797(17)30483-X 10.1016/j.amepre.2017.08.028 Globally, uptake of health screening in men remains low and the effectiveness of interventions to promote screening uptake in men is not well established. This review aimed (...) to determine the effectiveness of interventions in improving men's uptake of and intention to undergo screening, including interventions using information and communication technology and a male-sensitive approach. Studies were sourced from five electronic databases (October 2015), experts, and references of included studies. This study included RCTs or cluster RCTs that recruited men and reported uptake of or intention to undergo screening. Two researchers independently performed study selection

EvidenceUpdates2018

197. Symptom screening for active tuberculosis in pregnant women living with HIV.

Symptom screening for active tuberculosis in pregnant women living with HIV. This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows: To assess the accuracy of the four-symptom screen (cough, fever, night sweats, or weight loss) for identifying active TB in pregnant PLHIV who are screened in an outpatient or community setting. To investigate potential sources of heterogeneity of the accuracy of the four-symptom screen between studies including: ART (...) status, CD4 cell count, gestational age, pregnancy stage (pregnancy vs. postpartum), screening test definition of cough (any cough vs. cough greater than 2 weeks).To describe the accuracy of single symptoms included within the four-symptom screen, additioal symptoms or symptom combinations, for identifying active TB in pregnant PLHIV. For example, additional symptoms may include failure to gain weight or fatigue.

Cochrane2018

198. Newborn screening for galactosaemia.

Newborn screening for galactosaemia. BACKGROUND: Classical galactosaemia is an autosomal recessive inborn error of metabolism caused by a deficiency of the enzyme galactose-1-phosphate uridyltransferase. This is a rare and potentially lethal condition that classically presents in the first week of life once milk feeds have commenced. Affected babies may present with any or all of the following: cataracts; fulminant liver failure; prolonged jaundice; or Escherichia coli sepsis. Once (...) the diagnosis is suspected, feeds containing galactose must be stopped immediately and replaced with a soya-based formula. The majority of babies will recover, however a number will not survive. There are long-term complications of galactosaemia, despite treatment, including learning disabilities and female infertility. It has been postulated that galactosaemia could be detected on newborn screening and this would prevent the immediate severe liver dysfunction and sepsis. OBJECTIVES: To assess whether

Cochrane2017

199. Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study

Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study REGULARARTICLE Bone disease in monoclonal gammopathy of undetermined signi?cance: results from a screened population-based study Sigrun Thorsteinsdottir, 1,2 Sigrun H. Lund, 2 Ebba K. Lindqvist, 3 Marianna Thordardottir, 2 Gunnar Sigurdsson, 4 Rene Costello, 5 DebraBurton, 5 HlifSteingrimsdottir, 1 VilmundurGudnason, 2,4 GudnyEiriksdottir, 4 KristinSiggeirsdottir, 4 TamaraB.Harris (...) ,NationalInstitutesofHealth,Bethesda,MD;and 7 MyelomaService,Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY Key Points ? Individuals with MGUS did not have a de- creased BMD com- pared with others in a screened population. ? Individuals with MGUS had an increased bone volume at the hip and lumbar spine compared with others. Previousstudieshaveshownthatindividualswithmonoclonalgammopathyof undeterminedsigni?cance(MGUS)haveanincreasedriskoffractures,althoughthe

Blood advances2017 Full Text: Link to full Text with Trip Pro

200. Effect of HPV vaccination and cervical cancer screening in England by ethnicity: a modelling study

Effect of HPV vaccination and cervical cancer screening in England by ethnicity: a modelling study Redirecting

The Lancet. Public health2017 Full Text: Link to full Text with Trip Pro